Annual EBIT
-$2.59 M
-$2.30 M-790.66%
December 31, 2023
Summary
- As of February 7, 2025, BGLC annual earnings before interest & taxes is -$2.59 million, with the most recent change of -$2.30 million (-790.66%) on December 31, 2023.
- During the last 3 years, BGLC annual EBIT has fallen by -$3.87 million (-303.61%).
- BGLC annual EBIT is now -303.61% below its all-time high of $1.27 million, reached on December 1, 2020.
Performance
BGLC EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$1.34 M
-$1.60 M-616.05%
September 30, 2024
Summary
- As of February 7, 2025, BGLC quarterly earnings before interest & taxes is -$1.34 million, with the most recent change of -$1.60 million (-616.05%) on September 30, 2024.
- Over the past year, BGLC quarterly EBIT has dropped by -$1.60 million (-616.05%).
- BGLC quarterly EBIT is now -224.60% below its all-time high of $1.07 million, reached on March 1, 2020.
Performance
BGLC Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$899.60 K
+$1.19 M+56.97%
September 30, 2024
Summary
- As of February 7, 2025, BGLC TTM earnings before interest & taxes is -$899.60 thousand, with the most recent change of +$1.19 million (+56.97%) on September 30, 2024.
- Over the past year, BGLC TTM EBIT has increased by +$1.19 million (+56.97%).
- BGLC TTM EBIT is now -170.62% below its all-time high of $1.27 million, reached on December 1, 2020.
Performance
BGLC TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
BGLC EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -790.7% | -616.0% | +57.0% |
| 3 y3 years | -303.6% | -2543.5% | -138.9% |
| 5 y5 years | -4429.9% | -2543.5% | -138.9% |
BGLC EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -345.6% | at low | -616.0% | +47.1% | -185.2% | +69.8% |
| 5 y | 5-year | -303.6% | at low | -224.6% | +47.1% | -170.6% | +69.8% |
| alltime | all time | -303.6% | at low | -224.6% | +47.1% | -170.6% | +69.8% |
BioNexus Gene Lab EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.34 M(-616.0%) | -$899.60 K(-57.0%) |
| Jun 2024 | - | $259.20 K(-428.1%) | -$2.09 M(-20.3%) |
| Mar 2024 | - | -$79.00 K(-130.6%) | -$2.62 M(+1.1%) |
| Dec 2023 | -$2.59 M(+790.7%) | $257.80 K(-110.2%) | -$2.59 M(-12.8%) |
| Sep 2023 | - | -$2.53 M(+828.9%) | -$2.97 M(+482.3%) |
| Jun 2023 | - | -$272.20 K(+437.9%) | -$510.70 K(+35.6%) |
| Mar 2023 | - | -$50.60 K(-58.8%) | -$376.50 K(+29.3%) |
| Dec 2022 | -$291.20 K(-127.6%) | -$122.70 K(+88.2%) | -$291.20 K(-993.3%) |
| Sep 2022 | - | -$65.20 K(-52.8%) | $32.60 K(-93.1%) |
| Jun 2022 | - | -$138.00 K(-497.7%) | $470.40 K(-37.1%) |
| Mar 2022 | - | $34.70 K(-82.7%) | $748.40 K(-29.1%) |
| Dec 2021 | $1.06 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | $201.10 K(-46.0%) | $1.06 M(+24.0%) |
| Sep 2021 | - | $372.60 K(+166.1%) | $851.70 K(+18.9%) |
| Jun 2021 | - | $140.00 K(-59.1%) | $716.40 K(+32.1%) |
| Mar 2021 | - | $342.10 K(<-9900.0%) | $542.40 K(-57.4%) |
| Dec 2020 | $1.27 M(-562.0%) | -$3000.00(-101.3%) | $1.27 M(+6.1%) |
| Sep 2020 | - | $237.30 K(-797.9%) | $1.20 M(+32.2%) |
| Jun 2020 | - | -$34.00 K(-103.2%) | $907.60 K(+4.0%) |
| Mar 2020 | - | $1.07 M(-1503.3%) | $872.40 K(-433.9%) |
| Dec 2019 | -$275.70 K(-560.3%) | -$76.50 K(+38.1%) | -$261.30 K(+41.4%) |
| Sep 2019 | - | -$55.40 K(-19.9%) | -$184.80 K(+42.8%) |
| Jun 2019 | - | -$69.20 K(+15.0%) | -$129.40 K(+115.0%) |
| Mar 2019 | - | -$60.20 K | -$60.20 K |
| Dec 2018 | $59.90 K | - | - |
FAQ
- What is BioNexus Gene Lab annual earnings before interest & taxes?
- What is the all time high annual EBIT for BioNexus Gene Lab?
- What is BioNexus Gene Lab annual EBIT year-on-year change?
- What is BioNexus Gene Lab quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for BioNexus Gene Lab?
- What is BioNexus Gene Lab quarterly EBIT year-on-year change?
- What is BioNexus Gene Lab TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for BioNexus Gene Lab?
- What is BioNexus Gene Lab TTM EBIT year-on-year change?
What is BioNexus Gene Lab annual earnings before interest & taxes?
The current annual EBIT of BGLC is -$2.59 M
What is the all time high annual EBIT for BioNexus Gene Lab?
BioNexus Gene Lab all-time high annual earnings before interest & taxes is $1.27 M
What is BioNexus Gene Lab annual EBIT year-on-year change?
Over the past year, BGLC annual earnings before interest & taxes has changed by -$2.30 M (-790.66%)
What is BioNexus Gene Lab quarterly earnings before interest & taxes?
The current quarterly EBIT of BGLC is -$1.34 M
What is the all time high quarterly EBIT for BioNexus Gene Lab?
BioNexus Gene Lab all-time high quarterly earnings before interest & taxes is $1.07 M
What is BioNexus Gene Lab quarterly EBIT year-on-year change?
Over the past year, BGLC quarterly earnings before interest & taxes has changed by -$1.60 M (-616.05%)
What is BioNexus Gene Lab TTM earnings before interest & taxes?
The current TTM EBIT of BGLC is -$899.60 K
What is the all time high TTM EBIT for BioNexus Gene Lab?
BioNexus Gene Lab all-time high TTM earnings before interest & taxes is $1.27 M
What is BioNexus Gene Lab TTM EBIT year-on-year change?
Over the past year, BGLC TTM earnings before interest & taxes has changed by +$1.19 M (+56.97%)